

November 26, 2025
JCR Pharmaceuticals Co., Ltd.

JCR Organizes and Conducts API Plant Tour for Local Residents

Hyogo, Japan – November 26, 2025 – [JCR Pharmaceuticals Co., Ltd.](#) (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, held its second plant tour for local residents at the Kobe Science Park Center (“KSPC”) in Nishi-ku, Kobe City on November 22. The tour provided local residents with a better understanding of the company's business activities.



Presentation on company profile and production facilities



New Formulation Plant (under construction)
adjacent to the API facility

KSPC is JCR's newest active pharmaceutical ingredient (API) plant, completed in November 2022. Twenty-five local residents, including elementary school and high school students, participated in the tour.

After a presentation about JCR's focus on rare diseases and the manufacturing process of biopharmaceuticals, the participants toured the plant and learned that the new formulation plant commenced construction in February 2025. Participants shared impressions and thoughts after the tour, such as: "I gained a good understanding of the drug manufacturing process," and "it was great to participate in my first factory tour and learn about rare diseases and corporate activities."

In line with JCR's corporate philosophy -- "We create treatments that go beyond rare disease to solve the world's most complex healthcare challenges" -- we will engage in community contribution activities and will continue to meet the challenge of delivering pharmaceuticals that only JCR can provide.



For more information about KSPC, please check here:
<https://ssl4.eir-parts.net/doc/4552/tdnet/2200173/00.pdf>

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: <https://jcrpharm.com/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###